Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMYRIS, INC.AMRS · Entity 91367 | Director | August 05, 2020 | August 08, 2020 |
| CODEXIS, INC.CDXS · Entity 6428 | Director | June 14, 2022 | June 16, 2022 |
| Sana Biotechnology, Inc.SANA · Entity 4870 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMYRIS, INC.
Report date August 05, 2020 · Filed August 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,793 |
Reported balance
After 2020-08-05 transaction · row 1
1 source rowRow 1 · 2020-08-05 · Grant · Acquired 2,266 · Balance 45,793 F1: Represents a restricted stock unit award that vests as to 100% of the units on August 5, 2021. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.94 · Expires 2030-08-05 | Direct | 3,466 |
Reported balance
After 2020-08-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-08-05 · Grant · Acquired 3,466 · Balance 3,466 F2: Stock option vests as to 100% of the shares underlying the stock option on August 5, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award that vests as to 100% of the units on August 5, 2021.
F2: Stock option vests as to 100% of the shares underlying the stock option on August 5, 2021.
CODEXIS, INC.
Report date June 14, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,785 |
Reported balance
After 2022-06-14 transaction · row 1
1 source rowRow 1 · 2022-06-14 · Grant · Acquired 11,273 · Balance 53,785 F1: The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.
Sana Biotechnology, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-03 | Direct | 90,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 90,000 · Balance 90,000 F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ANDEAVOR LLC
Report date October 01, 2018 · Filed October 02, 2018
Section 16 reporting ended · disclosed 2018-10-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-10-01 transaction · row 1
1 source rowRow 1 · 2018-10-01 · Disposition to issuer · Disposed 6,682 · Balance 0 F1: Includes 1,145 restricted stock units. F2: Pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among the Issuer, Marathon Petroleum Corporation ("MPC"), Mahi Inc. and Mahi LLC (as amended, the "Merger Agreement"), at the effective time, each outstanding share of the Issuer's common stock was cancelled and became exchangeable for, at the holder's election, either $152.27 in cash or 1.87 shares of MPC common stock, subject to an allocation and proration whereby the outstanding shares of Issuer's common stock would be exchanged for approximately $3.5 billion in cash with the balance of shares exchanged for MPC shares, and each restricted stock unit was accelerated and cancelled in exchange for $152.27 in cash. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-10-01 · Disposition to issuer · Disposed 6,786 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time, each restricted stock unit for which the reporting person had previously elected to defer distribution was accelerated and cancelled in exchange for $152.27 in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,145 restricted stock units.
F2: Pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among the Issuer, Marathon Petroleum Corporation ("MPC"), Mahi Inc. and Mahi LLC (as amended, the "Merger Agreement"), at the effective time, each outstanding share of the Issuer's common stock was cancelled and became exchangeable for, at the holder's election, either $152.27 in cash or 1.87 shares of MPC common stock, subject to an allocation and proration whereby the outstanding shares of Issuer's common stock would be exchanged for approximately $3.5 billion in cash with the balance of shares exchanged for MPC shares, and each restricted stock unit was accelerated and cancelled in exchange for $152.27 in cash.
F3: Pursuant to the Merger Agreement, at the effective time, each restricted stock unit for which the reporting person had previously elected to defer distribution was accelerated and cancelled in exchange for $152.27 in cash.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 5, 2026 20:43 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001309988-26-000002 · primarydocument.xml · derivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:38 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001562180-25-004639 · primarydocument.xml · derivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:21 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 54,278 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001562180-24-004837 · primarydocument.xml · derivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,278 Underlying: Common Stock · 54,278 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| June 06, 2024 Filed Jul 15, 2024 20:13 UTC Amendment | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001562180-24-005724 · primarydocument.xml · derivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2034-06-05 F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 20:57 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 25,000 | $9.45 | $236,300.00 |
DisclosureSEC source: 0001562180-24-002538 · primarydocument.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,250 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.44 to $9.49, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:31 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001562180-23-005026 · primarydocument.xml · derivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:14 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 11,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-012977 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,785 F1 · shares: The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 22:34 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001562180-22-004941 · primarydocument.xml · derivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 23:51 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | PurchaseCommon Stock | 28,000 | $7.30 | $204,400.00 |
DisclosureSEC source: 0001562180-22-002871 · primarydocument.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,250 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.14 to $7.40, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 20:05 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 8,000 | $16.79 | $134,304.80 |
DisclosureSEC source: 0001567619-22-007047 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,512 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2021. F2 · price: The shares were sold in multiple transactions at per share prices ranging from $16.474 to $17.13. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 13, 2021 Filed Dec 14, 2021 21:05 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 200 | $32.14 | $6,428.00 |
DisclosureSEC source: 0001567619-21-022019 · doc1.xml · nonDerivative · entry 2 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,512 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2021. Read SEC document |
| December 13, 2021 Filed Dec 14, 2021 21:05 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 7,800 | $31.59 | $246,391.86 |
DisclosureSEC source: 0001567619-21-022019 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,712 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2021. F2 · price: The shares were sold in multiple transactions at per share prices ranging from $31.09 to $31.95. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 20:20 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 20,000 | $20.31 | $406,186.00 |
DisclosureSEC source: 0001567619-21-012326 · doc1.xml · nonDerivative · entry 2 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,512 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2021. F3 · price: The shares were sold in multiple transactions at per share prices ranging from $19.70 to $20.65. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:20 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 4,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012326 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,512 F1 · shares: The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 20:48 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 10,000 | $25.15 | $251,547.00 |
DisclosureSEC source: 0001567619-21-007769 · doc1.xml · nonDerivative · entry 2 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,716 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2021. F3 · price: The shares were sold in multiple transactions at per share prices ranging from $24.977 to $25.50. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:48 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 10,000 | $24.27 | $242,732.00 |
DisclosureSEC source: 0001567619-21-007769 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,716 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2021. F2 · price: The shares were sold in multiple transactions at per share prices ranging from $24.07 to $24.52. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:14 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $25.00 | $0.00 |
DisclosureSEC source: 0000899243-21-005065 · doc4.xml · derivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-02-02 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on February 3, 2022. Read SEC document |
| February 03, 2021 Filed Feb 18, 2021 23:54 UTC Amendment | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 23,591 | $0.00 Strike: $25.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007185 · doc4a.xml · derivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,591 Underlying: Common Stock · 23,591 shares Expires 2031-02-02 F1 · shares: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. F2 · derivative.exercise_date: The stock option shall vest and become exercisable in full on February 3, 2022. F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. F1 · balance_after: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. Read SEC document |
| August 05, 2020 Filed Aug 8, 2020 00:00 UTC | AMYRIS, INC. AMRS · Entity 91367 | GrantWarrant (Right to Buy) · Derivative | 3,466 | $0.00 Strike: $4.94 | $0.00 |
DisclosureSEC source: 0001365916-20-000141 · wf-form4_159684469919502.xml · derivative · entry 2 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,466 Underlying: Common Stock · 3,466 shares Expires 2030-08-05 F2 · derivative.exercise_date: Stock option vests as to 100% of the shares underlying the stock option on August 5, 2021. Read SEC document |
| August 05, 2020 Filed Aug 8, 2020 00:00 UTC | AMYRIS, INC. AMRS · Entity 91367 | GrantCommon Stock | 2,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001365916-20-000141 · wf-form4_159684469919502.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,793 F1 · shares: Represents a restricted stock unit award that vests as to 100% of the units on August 5, 2021. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:11 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 8,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-012367 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,716 F1 · shares: Restricted stock. The shares vest on the earlier of June 16, 2021 or the date of the Issuer's 2021 annual meeting of stockholders. Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 01:37 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 10,671 | $3.10 | $33,080.10 |
DisclosureSEC source: 0001365916-19-000091 · edgar.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,527 Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 23:53 UTC | AMYRIS, INC. AMRS · Entity 91367 | GrantStock Option (Right to Buy) · Derivative | 3,466 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001365916-19-000071 · edgar.xml · derivative · entry 2 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,466 Underlying: Common Stock · 3,466 shares Expires 2029-10-23 F2 · derivative.exercise_date: Stock option vests as to 100% of the shares underlying the stock option on October 23, 2020. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 23:53 UTC | AMYRIS, INC. AMRS · Entity 91367 | GrantCommon Stock | 2,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001365916-19-000071 · edgar.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,198 F1 · shares: Represents a restricted stock unit award that vests as to 100% of the units on October 23, 2020. Read SEC document |
| September 06, 2019 Filed Sep 6, 2019 23:34 UTC | CODEXIS, INC. CDXS · Entity 6428 | PurchaseCommon Stock | 5,000 | $13.74 | $68,676.00 |
DisclosureSEC source: 0001567619-19-018011 · doc1.xml · nonDerivative · entry 2 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,764 F2 · price: This transaction was executed in multiple trades in prices ranging from $13.7299 to $13.7358, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 23:34 UTC | CODEXIS, INC. CDXS · Entity 6428 | PurchaseCommon Stock | 3,000 | $13.62 | $40,846.80 |
DisclosureSEC source: 0001567619-19-018011 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,764 F1 · price: This transaction was executed in multiple trades in prices ranging from $13.5999 to $13.6234, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 20:32 UTC | CODEXIS, INC. CDXS · Entity 6428 | PurchaseCommon Stock | 6,000 | $13.97 | $83,812.80 |
DisclosureSEC source: 0001567619-19-017888 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,764 F1 · price: This transaction was executed in multiple trades in prices ranging from $13.96 to $13.9695, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 13:16 UTC | CODEXIS, INC. CDXS · Entity 6428 | PurchaseCommon Stock | 12,000 | $12.94 | $155,280.00 |
DisclosureSEC source: 0001567619-19-017555 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,764 F1 · price: This transaction was executed in multiple trades in prices ranging from $12.80 to $13.04, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:14 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 4,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013341 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,764 F1 · shares: Restricted stock. The shares vest on the earlier of June 11, 2020 or the date of the Issuer's 2020 annual meeting of stockholders. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 23:39 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 7,100 | $18.61 | $132,163.66 |
DisclosureSEC source: 0001567619-18-008549 · doc1.xml · nonDerivative · entry 3 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,817 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018. F4 · price: This transaction was executed in multiple trades in prices ranging from $18.26 to $19.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 23:39 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 17,900 | $17.50 | $313,328.76 |
DisclosureSEC source: 0001567619-18-008549 · doc1.xml · nonDerivative · entry 2 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,917 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018. F3 · price: This transaction was executed in multiple trades in prices ranging from $17.23 to $18.22, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 23:39 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 25,000 | $19.22 | $480,457.50 |
DisclosureSEC source: 0001567619-18-008549 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,817 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018. F2 · price: This transaction was executed in multiple trades in prices ranging from $18.99 to $19.48, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 21:33 UTC | ANDEAVOR LLC ANDV · Entity 143162 | Disposition to issuerRestricted Stock Units · Derivative | 6,786 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-025933 · doc4.xml · derivative · entry 2 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,786 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, at the effective time, each restricted stock unit for which the reporting person had previously elected to defer distribution was accelerated and cancelled in exchange for $152.27 in cash. F3 · price: Pursuant to the Merger Agreement, at the effective time, each restricted stock unit for which the reporting person had previously elected to defer distribution was accelerated and cancelled in exchange for $152.27 in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time, each restricted stock unit for which the reporting person had previously elected to defer distribution was accelerated and cancelled in exchange for $152.27 in cash. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the effective time, each restricted stock unit for which the reporting person had previously elected to defer distribution was accelerated and cancelled in exchange for $152.27 in cash. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 21:33 UTC | ANDEAVOR LLC ANDV · Entity 143162 | Disposition to issuerCommon Stock | 6,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-025933 · doc4.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 1,145 restricted stock units. F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among the Issuer, Marathon Petroleum Corporation ("MPC"), Mahi Inc. and Mahi LLC (as amended, the "Merger Agreement"), at the effective time, each outstanding share of the Issuer's common stock was cancelled and became exchangeable for, at the holder's election, either $152.27 in cash or 1.87 shares of MPC common stock, subject to an allocation and proration whereby the outstanding shares of Issuer's common stock would be exchanged for approximately $3.5 billion in cash with the balance of shares exchanged for MPC shares, and each restricted stock unit was accelerated and cancelled in exchange for $152.27 in cash. Read SEC document |
| September 19, 2018 Filed Sep 20, 2018 22:30 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 25,000 | $17.94 | $448,427.50 |
DisclosureSEC source: 0001567619-18-002972 · doc1.xml · nonDerivative · entry 2 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,817 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018. F3 · price: This transaction was executed in multiple trades in prices ranging from $17.65 to $18.275, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 22:30 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 25,000 | $18.47 | $461,750.00 |
DisclosureSEC source: 0001567619-18-002972 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,817 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018. F2 · price: This transaction was executed in multiple trades in prices ranging from $18.20 to $18.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 16, 2018 Filed Aug 21, 2018 00:51 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 150,340 | $14.45 | $2,172,413.00 |
DisclosureSEC source: 0001567619-18-001507 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Patrick & Shu-O Yang TTEES Disclosed balance after: 0 F1 · kind: The reporting person contributed common stock to an exchange fund in exchange for shares of the exchange fund. The common stock was valued at $14.45 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F1 · price: The reporting person contributed common stock to an exchange fund in exchange for shares of the exchange fund. The common stock was valued at $14.45 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F2 · balance_after: Shares in Column 5 reflect the Reporting Person's prior transfer of shares into his family trust. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 23:34 UTC | AMYRIS, INC. AMRS · Entity 91367 | PurchaseCommon Stock | 15,000 | $7.66 | $114,900.00 |
DisclosureSEC source: 0001567619-18-001231 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,932 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.62 to $7.67 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1). Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 23:51 UTC | AMYRIS, INC. AMRS · Entity 91367 | PurchaseCommon Stock | 10,000 | $7.71 | $77,100.00 |
DisclosureSEC source: 0001567619-18-000671 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,932 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.69 to $7.71 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1). Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 23:37 UTC | AMYRIS, INC. AMRS · Entity 91367 | GrantStock Option (Right to Buy) · Derivative | 3,466 | $0.00 Strike: $6.96 | $0.00 |
DisclosureSEC source: 0001140361-18-035469 · doc1.xml · derivative · entry 2 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,466 Underlying: Common Stock · 3,466 shares Expires 2028-08-01 F2 · derivative.exercise_date: Stock option vests as to 100% of the shares underlying the stock option on August 1, 2019. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 23:37 UTC | AMYRIS, INC. AMRS · Entity 91367 | GrantCommon Stock | 2,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-035469 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,932 F1 · shares: Represents a restricted stock unit award that vests as to 100% of the units on August 1, 2019. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 22:36 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 25,000 | $15.52 | $387,982.50 |
DisclosureSEC source: 0001140361-18-033065 · doc1.xml · nonDerivative · entry 2 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,157 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018. F3 · price: This transaction was executed in multiple trades in prices ranging from $15.25 to $15.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 22:36 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 25,000 | $15.40 | $384,920.00 |
DisclosureSEC source: 0001140361-18-033065 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,157 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018. F2 · price: This transaction was executed in multiple trades in prices ranging from $15.10 to $15.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 00:59 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 5,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-028287 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,157 F1 · shares: Restricted stock. The shares vest on the earlier of June 11, 2019 or the date of the Issuer's 2019 annual meeting of stockholders. Read SEC document |
| May 04, 2018 Filed May 9, 2018 07:11 UTC | ANDEAVOR LLC ANDV · Entity 143162 | GrantCommon Stock | 1,145 | $0.00 | $0.00 |
DisclosureSEC source: 0000050104-18-000122 · wf-form4_152586423297087.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,682 F1 · security: Annual non-employee director restricted stock unit award granted under the Issuer's 2018 Long-Term Incentive Plan. The restricted stock units are scheduled to vest on the first anniversary of the grant date. Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 23:33 UTC | AMYRIS, INC. AMRS · Entity 91367 | GrantStock Option (Right to Buy) · Derivative | 1,733 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001365916-17-000062 · edgar.xml · derivative · entry 2 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,733 Underlying: Common Stock · 1,733 shares Expires 2027-08-02 F3 · derivative.exercise_date: Stock option vests as to 100% of the total number of shares subject to the option on August 2, 2018. Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 23:33 UTC | AMYRIS, INC. AMRS · Entity 91367 | GrantCommon Stock | 1,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001365916-17-000062 · edgar.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,666 F1 · shares: Represents a restricted stock unit award that vests as to 100% of the units subject to the award on August 2, 2018. F2 · balance_after: Reflects a 1-for-15 reverse stock split which became effective on June 5, 2017. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 22:44 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 17,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-025414 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,234 F1 · shares: Restricted stock. The shares vest on the earlier of June 14, 2018 or the date of the Issuer's 2017 annual meeting of stockholders. Read SEC document |
| May 19, 2017 Filed May 22, 2017 23:36 UTC | AMYRIS, INC. AMRS · Entity 91367 | PurchaseCommon Stock | 100,000 | $0.29 | $28,940.00 |
DisclosureSEC source: 0001365916-17-000032 · edgar.xml · nonDerivative · entry 3 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,000 F3 · shares: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.2811 to $0.2901 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3). Read SEC document |
| May 19, 2017 Filed May 22, 2017 23:36 UTC | AMYRIS, INC. AMRS · Entity 91367 | PurchaseCommon Stock | 100,000 | $0.29 | $29,440.00 |
DisclosureSEC source: 0001365916-17-000032 · edgar.xml · nonDerivative · entry 2 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,000 F2 · shares: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.2944 to $0.2958 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.